Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 <b>
                     <i>in Vitro</i>
                  </b>

Houghton, Peter J.; Germain, Glen S.; Harwood, Franklin C.; Schuetz, John D.; Stewart, Clinton F.; Buchdunger, Elisabeth; Traxler, Peter

doi:10.1158/0008-5472.can-03-3344

Cited by 302 publications

(209 citation statements)

References 8 publications

Supporting

Mentioning

187

Contrasting

Unclassified

Order By: Relevance

“…Conflicting results have been published regarding the ability of BCRP to transport this compound. In one study, overexpression of BCRP in Saos2 cells did not confer resistance to imatinib, and accumulation and efflux of this drug were not affected by BCRP expression and ATP depletion (Houghton et al, 2004), suggesting that imatinib is not a substrate of BCRP. Rather, imatinib may serve as a potent BCRP inhibitor thereby enabling reversal of BCRP-mediated resistance to topotecan and SN-38 (Houghton et al, 2004).…”

Section: Imatinibmentioning

confidence: 99%

“…In one study, overexpression of BCRP in Saos2 cells did not confer resistance to imatinib, and accumulation and efflux of this drug were not affected by BCRP expression and ATP depletion (Houghton et al, 2004), suggesting that imatinib is not a substrate of BCRP. Rather, imatinib may serve as a potent BCRP inhibitor thereby enabling reversal of BCRP-mediated resistance to topotecan and SN-38 (Houghton et al, 2004). Similarly, accumulation of mitoxantrone in primary chronic myeloid leukaemia (CML) CD34 þ cells overexpressing BCRP was significantly increased by 5 mM of imatinib, confirming the activity of this TKI as a BCRP inhibitor (Jordanides et al, 2006).…”

Section: Imatinibmentioning

confidence: 99%

See 1 more Smart Citation

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors

2008

View full text Add to dashboard Cite

show abstract

Section: Imatinibmentioning

confidence: 99%

Section: Imatinibmentioning

confidence: 99%

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors

2008

View full text Add to dashboard Cite

show abstract

“…However, the neurotoxicity of fumitremorgin C prevents its use in vivo (34). Some clinically used tyrosine kinase inhibitors such as gefitinib and imatinib have also been shown to inhibit BCRP (8,35). However, they have intrinsic anticancer activity.…”

Section: Enhancing Effect Of Yho-13351 On Antitumor Activity Of Irinomentioning

confidence: 99%

Novel Acrylonitrile Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug ResistanceIn VitroandIn Vivo

Yamazaki

Nishiyama

Furuta

et al. 2011

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Breast cancer resistance protein (BCRP/ABCG2) confers resistance to anticancer drugs such as 7-ethyl-10-hydroxycamptothecin (SN-38, an active metabolite of irinotecan), mitoxantrone, and topotecan. In this study, we examined the reversing effects of YHO-13177, a novel acrylonitrile derivative, and its water-soluble diethylaminoacetate prodrug YHO-13351 on the BCRP-mediated drug resistance. YHO-13177 potentiated the cytotoxicity of SN-38, mitoxantrone, and topotecan in both BCRP-transduced human colon cancer HCT116 (HCT116/BCRP) cells and SN-38-resistant human lung cancer A549 (A549/SN4) cells that express BCRP, but had little effect in the parental cells. In addition, YHO-13177 potentiated the cytotoxicity of SN-38 in human lung cancer NCI-H460 and NCI-H23, myeloma RPMI-8226, and pancreatic cancer AsPC-1 cells that intrinsically expressed BCRP. In contrast, it had no effect on P-glycoprotein-mediated paclitaxel resistance in MDR1-transduced human leukemia K562 cells and multidrug resistance-related protein 1-mediated doxorubicin resistance in MRP1-transfected human epidermoid cancer KB-3-1 cells. YHO-13177 increased the intracellular accumulation of Hoechst 33342, a substrate of BCRP, at 30 minutes and partially suppressed the expression of BCRP protein at more than 24 hours after its treatment in both HCT116/BCRP and A549/SN4 cells. In mice, YHO-13351 was rapidly converted into YHO-13177 after its oral or intravenous administration. Coadministration of irinotecan with YHO-13351 significantly increased the survival time of mice inoculated with BCRPtransduced murine leukemia P388 cells and suppressed the tumor growth in an HCT116/BCRP xenograft model, whereas irinotecan alone had little effect in these tumor models. These findings suggest that YHO-13351, a prodrug of YHO-13177, could be clinically useful for reversing BCRP-mediated drug resistance in cancer chemotherapy.

show abstract

“…Imatinib, a tyrosine kinase inhibitor, is a promising molecularly targeted chemotherapeutic agent. It has been shown to be both a substrate and inhibitor of ABCG2, thus allowing its efflux by a stem cell that express this ABC transporter (Houghton et al, 2004;Burger et al, 2004). In-depth mechanistic studies in imatinib-resistant leukemia cells revealed several "acquired" mutations in the kinase domain of ABL in patient with CML or with AML associated with t(9;22)(q34;q11).…”

Section: Working Models Of Cancer Drug Resistancementioning

confidence: 99%

“…TKIs are an important new class of molecularly targeted chemotherapeutic agents that specifically inhibit several oncogenic tyrosine kinases, thereby regulating cancer proliferation, invasion, metastasis and angiogenesis. The first TKI that was approved for CML, imatinib, has been shown to reverse MDR by inhibiting ABCB1(Pgp) (Hegedus et al, 2002) and ABCG2 (Houghton et al, 2004). A few other TKIs were also demonstrated to reverse drug resistance mediated by MDR transporters in various in vitro and in vivo models (reviewed in Wang & Fu, 2010).…”

Section: Novel Transporter Inhibitors May Hold Promise To Target Cscsmentioning

confidence: 99%

Multidrug Resistance Transporters – Roles in maintaining Cancer Stem-Like Cells

Tõ¹,

Kenneth²,

Fu³

2011

Stem Cells in Clinic and Research

View full text Add to dashboard Cite

Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro

Cited by 302 publications

References 8 publications

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors

Drug transporters: recent advances concerning BCRP and tyrosine kinase inhibitors

Novel Acrylonitrile Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug ResistanceIn VitroandIn Vivo

Multidrug Resistance Transporters – Roles in maintaining Cancer Stem-Like Cells

Contact Info

Product

Resources

About